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A framework for application of metabolic modeling
in yeast to predict the effects of nsSNV in human
orthologs
Hayley Dingerdissen1, Daniel S Weaver2, Peter D Karp2, Yang Pan1, Vahan Simonyan3 and Raja Mazumder1,4*

Abstract
Background: We have previously suggested a method for proteome wide analysis of variation at functional
residues wherein we identified the set of all human genes with nonsynonymous single nucleotide variation (nsSNV)
in the active site residue of the corresponding proteins. 34 of these proteins were shown to have a 1:1:1 enzyme:
pathway:reaction relationship, making these proteins ideal candidates for laboratory validation through creation and
observation of specific yeast active site knock-outs and downstream targeted metabolomics experiments. Here we
present the next step in the workflow toward using yeast metabolic modeling to predict human metabolic
behavior resulting from nsSNV.
Results: For the previously identified candidate proteins, we used the reciprocal best BLAST hits method followed
by manual alignment and pathway comparison to identify 6 human proteins with yeast orthologs which were
suitable for flux balance analysis (FBA). 5 of these proteins are known to be associated with diseases, including
ribose 5-phosphate isomerase deficiency, myopathy with lactic acidosis and sideroblastic anaemia, anemia due to
disorders of glutathione metabolism, and two porphyrias, and we suspect the sixth enzyme to have disease
associations which are not yet classified or understood based on the work described herein.
Conclusions: Preliminary findings using the Yeast 7.0 FBA model show lack of growth for only one enzyme,
but augmentation of the Yeast 7.0 biomass function to better simulate knockout of certain genes suggested
physiological relevance of variations in three additional proteins. Thus, we suggest the following four proteins for
laboratory validation: delta-aminolevulinic acid dehydratase, ferrochelatase, ribose-5 phosphate isomerase and
mitochondrial tyrosyl-tRNA synthetase. This study indicates that the predictive ability of this method will improve as
more advanced, comprehensive models are developed. Moreover, these findings will be useful in the development
of simple downstream biochemical or mass-spectrometric assays to corroborate these predictions and detect
presence of certain known nsSNVs with deleterious outcomes. Results may also be useful in predicting as yet
unknown outcomes of active site nsSNVs for enzymes that are not yet well classified or annotated.
Reviewers: This article was reviewed by Daniel Haft and Igor B. Rogozin.
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Background
An enyzme’s active site specificity is an important determinant of functional catalysis. For this reason, if a
nonsynonymous single nucleotide variation (nsSNV)
occurs at the active site, thereby changing an active site
amino acid residue, it is highly likely that enzyme activity
will be lost or altered [1-7]. It follows that pathway activity
should also be affected, with a potential end result of
disease [8-10] or lethality.
In our previous paper [11] we used the SNVDis Tool
[12], part of the High-performance Integrated Virtual
Environment (HIVE) tools suite (accessed at hive.biochemistry.gwu.edu) [13] to identify the entire set of 559
human proteins with nonsynonymous variation at an
active site residue resulting from a single nucleotide
variation. Pathway, substrate and product annotation was
manually retrieved from Kyoto Encyclopedia of Genes and
Genomes (KEGG) [14] for all possible proteins in the
dataset. To the best of our knowledge, a subset of 34 of
the original proteins had a 1 enzyme:1 pathway:1 substrate/product set ratio, meaning these enzymes catalyze a
single reaction for a single set of substrates and products
and are currently annotated to participate in a single
pathway. While there may be possible interaction between specified metabolites and alternative enzymes,
the 1:1:1 relationship ensures no alternative metabolic
interaction with the specified enzymes, thus making them
suitable candidates for in vivo laboratory validation.
For this paper, we used the reciprocal best BLAST
hits method [15] to query the set of 559 human active
site nsSNV proteins against the yeast (Saccharomyces
cerevisiae) proteome and, conversely, the top yeast protein hits back against the human proteome. We then
checked for active site residue conservation and pathway/
substrate/enzyme conservation between the 113 identified
human-yeast orthologous pairs. We found 6 proteins
which satisfied all criteria, 5 of which had human disease associations including anemias, porphyrias and
others. The high incidence of dysfunction annotated
among these active-site-nsSNV-containing proteins reinforces the notion that mutations in the active site disrupt normal enzyme and/or pathway activity. Although it
may seem intuitive that the active site modifications are to
blame for these disease associations, it is surprising to
note that the disease-related annotations are not currently
attributed to the active site variations for the 5 proteins in
question, but are assigned to other sequence variations or
causes.
Merely studying genomic variation may not be enough
to determine the effects of active site variation, however,
as one needs to examine the interactions and physiological outcome within the context of the cell, organ, or
entire system [16]. Metabolic modeling is our attempt
to test the impact of active site variation in a more
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meaningful way as such methods get more sophisticated.
To this end, we used the Yeast 7.0 flux balance analysis
(FBA) model [17] to predict the effects of deleting these 6
proteins, constructed with the relevant nsSNV active site
mutation, on the growth of yeast. Since several of these
proteins are involved in production of important metabolites that are not contained within the Yeast 7.0 biomass
function, we repeated the analysis using a revised biomass
equation that incorporates the relevant metabolites. FBA
is an established mathematical and computational approach
for studying metabolic networks [18,19]. FBA modeling has
a number of biotech applications as it allows programmatic
prediction of a metabolic phenotype using in silico computations of reaction stoichiometry without using reaction
kinetics [20-22]. FBA results have been shown to correlate
well with experimental observations [23].
In the future, predictions given by this in silico cell
model can be subjected to laboratory validation using
yeast cultures with site-induced mutagenesis to alter the
proper active site residue and observe the outcomes with
respect to growth rate, substrate and product quantities,
byproduct generation and general viability. We reason
that the conservation of these protein sequences from
yeast to humans, in conjunction with conserved active
site residues and conserved pathway interplay, provides
strong evidence that similar outcomes are likely to result
from mutations in the human orthologs [24].
Our overarching goal is to better understand phenotypic
effects of nsSNVs on the active site of enzymes. Although
we use a small set of enzymes here to perform a preliminary proof of principle, this experiment lays the foundation
for a method of cellular modeling that will move toward
an “omics” approach with potential predictive ability.
Similar large-scale studies already demonstrate the utility
of this type of approach to predict metabolite concentrations related to environmental conditions [25], enzyme
phosphorylation [26] and even whole gene deletion [27],
but to the best of our knowledge there is no such effort to
apply a metabolomics approach to the analysis of activesite- nsSNV-containing proteins to yield predictive and/or
diagnostic information.

Results and discussion
The complete human and yeast proteomes, and all protein
subsets, available from UniProtKB/Swiss-Prot, provide
curated annotation information regarding both nsSNV
and active sites [28]. The dbSNP database [29] provides
additional information on variations and the Conserved
Domain Database (CDD) [30] provides additional information on active sites. The SNVDis tool uses this information
to return an output table with all human proteins containing nonsynonymous substitutions at the active site.
Note here that we do not discriminate between heterozygous and homozygous nsSNVs because pertinent
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information is unavailable for the majority of human
variation data. Previous findings imply that most nsSNVs
in active sites are rare or heterozygous because they are
expected to be selected against and, therefore, unlikely to
be observed in a homozygous pair [31]. Studies of consanguineous families may prove a good source for detection
of homozygous active site nsSNVs in the future, but there
are currently few documented cases [32] of catalytic
homozygote variants. This is problematic as currently
available models assume the haploid condition of a
yeast cell. Results of reducing the flux to zero in such a
model cannot be easily generalized to a diploid, heterozygous state unless known loss of function via haploinsufficiency or dominant negative phenotypes is established.
Although we cannot say with certainty that the variations
presented in this paper confer this phenotype, there is
literature evidencing the heterozygous loss of function
associated with active site mutations in a number of
mammalian genes including mouse DNA polymerase δ
[33], human DNA polymerase γ [34] and mammalian
11β-hydroxysteroid dehydrogenase type I [35]. Furthermore, the aforementioned murine study was extended
from studies of homologous mutations in haploid yeast.
Thus, while we cannot fully extend haploid modeling to
proteins in diploid organisms, we suggest that yeast
enzymes whose knockouts alter flux balance necessitate
further attention be given to their orthologous human
counterparts, for both homozygous and heterozygous variations. Specifically, we propose that haploid models could
still provide quantitative value toward the development of
predictive assays for highly conserved pathways in cases
of true loss of function due to heterozygous mutation at
human active sites.
A proteome-wide search in SNVDis returns 559 unique
human proteins (Additional file 1: Table A1) with nsSNV
at the active site. Subsequent pathway analysis using
annotations from KEGG shows a subset of 34 proteins
(updated from previous publication to include two additional proteins from the same set of 559 which were later
found to meet the criteria) with nsSNV at the active site
and a 1 enzyme:1 pathway:1 reaction relationship. Full
methods and discussion for these and other preliminary
results can be seen in the prior publication.
Reciprocal best BLAST hits method to identify human-yeast
ortholog pairs

To identify proteins from yeast (S. cerevisiae) orthologous
to the 559 active-site-nsSNV-containing human proteins,
the reciprocal best BLAST hits method was used. The sequences for the 559 active-site-nsSNV-containing human
proteins were extracted from UniProtKB/Swiss-Prot by
UniProt Accession and used as the query in a BLAST [36]
against the yeast proteome. Of the 559, 173 proteins have
no hits against the yeast proteome with E-value less than
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0.0001 and 146 proteins have significant hits but are
deemed to be paralogous. Thus, 240 of the 559 human
proteins are considered to have a one-way best hit. These
240 best-hit yeast proteins were then used as the query in
a second BLAST against the entire human proteome. Of
these 240, 127 have a unidirectional best-match such that
the highest scoring yeast match from the human BLAST
against the yeast proteome has an alternative highestscoring human match when queried against the entire
human proteome. This leaves 113 proteins with active
site nsSNV to have a reciprocal best-match ortholog in
yeast (Table 1, full reciprocal best BLAST hits data can
be shown in Additional file 1: Table A2).
Identification of candidate enzymes for in vivo validation

To be considered ideal for laboratory validation, we want
to first limit our consideration to the proteins in Table 2
which have a simple 1 enzyme:1 pathway:1 reaction relationship relationship. This 1:1:1 ratio drastically limits
the possibility for an enzyme to affect or be affected by
multiple metabolites during laboratory experiments. Of
the 34 potential candidates, 11 had no best hit and 10
had a one-way best hit, leaving 11 proteins as potential
candidates with reciprocal best-match orthologs.
We must also consider the case when the product of
an enzymatic reaction can be synthesized by alternative
means. For this paper, we decided to consider these cases
due to literature supporting biochemical importance of
dysfunction despite multiple pathways to product.
Additionally, we want to ensure the variable site of
interest, the active site, is conserved across ortholog pairs.
If functional residues are not conserved, we cannot say
that experimental observations resulting from a variation
in a yeast enzyme is at all indicative of outcomes of variation in the corresponding human enzyme. This was
checked by manual examination of alignments (Figure 1).
The minimum requirement for active site conservation is
that the residue(s) annotated as the active site residue(s)
are identical across species, although many of the humanyeast pairs have blocks of up 10 amino acids conserved
across species. 10 of the 11 ortholog pairs were conserved
at the active site.
We want to further limit wet-lab candidate enzymes to
those with no other orthologs or paralogs. Even though
the proteins under consideration at this point are reciprocal best-matches, proteins with closely related homologs
limit the confidence with which we can report results of
laboratory validation experiments. For example, if a human protein has a best match with a yeast protein which
has paralogs, we cannot be sure upon knockout of the enzyme that the paralogous proteins will not interfere in the
metabolism we are trying to assay. Exclusion of proteins
with orthologs and paralogs was performed by manually
examining alignments. This exclusion now reduces our list
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Table 1 Human proteins with active site nsSNV and their yeast ortholog match
Human protein

Yeast ortholog

Human protein

Yeast ortholog

Human protein

Yeast ortholog

Q9GZR2

Q08237

Q9P2J9

Q12511

Q15067

P13711

P49247

Q12189

Q9BZP6

Q06350

Q96S44

P53323

Q9UBZ4

P38207

O60825

P32604

O95154

P42884

Q14410

P32190

O15305

P07283

P78368

P23292

P51659

Q02207

Q9UNI6

Q02256

Q6PI48

P15179

P20618

P23724

Q96RR4

P43637

Q13164

Q00772

Q96T52

P46972

Q9NUW8

P38319

P06744

P12709

P08397

P28789

P00480

P05150

P11498

P32327

P04424

P04076

Q6IA69

P38795

P05186

P11491

P40818

P32571

Q04760

P50107

Q8TF76

P32789

Q8IWW8

P10127

P36873

P32598

P29120

P13134

P37268

P29704

Q9P2K8

P15442

Q8IWX5

P23501

Q96G46

Q06053

Q96GX9

P47095

Q96DP5

P32785

P48637

Q08220

Q13332

P25044

Q9Y3E5

P34222

P09467

P09201

P12955

P43590

P25789

P23638

Q9UGM6

P04803

P06132

P32347

P60484

P53916

P78549

P31378

O75191

P42826

P49917

Q08387

O96017

P39009

Q9H3S4

P35202

P32320

Q06549

Q7L3T8

P39965

P06737

P06738

Q9NSY1

P53974

Q9NYY3

P32562

Q13907

P15496

O60942

Q01159

O43426

P50942

P49841

P38615

Q9UGP5

P25615

O95363

P08425

P36871

P37012

Q9BUP3

P40008

P34949

P29952

Q9UBZ9

P12689

P54098

P15801

Q7L211

P42840

Q9HBY8

P12688

Q9UJM8

P00175

P07741

P49435

P07902

P08431

Q8WUX2

P32656

P13716

P05373

Q9Y2L1

Q08162

Q14249

P08466

P48449

P38604

Q96C11

Q04585

Q5VTY9

Q08929

P49336

P39073

O14818

P40303

Q86YJ6

P16120

Q8IZ73

Q12362

O00743

P20604

P12081

P07263

Q69YN2

P53255

Q5T2R2

P18900

Q9UQB9

P38991

Q99447

P33412

P04180

P40345

O14734

P41903

P30793

P51601

Q9Y3Q0

P47161

P14550

P14065

Q9BV23

P53750

O43175

P40054

P08243

P49090

P56937

Q12452

P22830

P16622

Q86V88

P40081

Q16769

P43599

O95336

P38858

Q8IXB1

P40564

Q15386

P53119

Q969P6

P04786

Q9Y3B8

P54964

Q9Y2H1

P53894

Q9Y2Z4

P48527

P00813

P53909

Q9UI42

P38836

Q9Y6R4

P53599

This table lists the pool of 113 reciprocal best match human-yeast ortholog pairs, a subset from the original 559 proteins with active site nsSNV.

of potential candidates to 6. Table 3 lists the active site
residue and surrounding conserved residues for these 6
proteins.
Finally, we want to make sure the ortholog pairs are
involved in similar pathways. If a human protein has

diverged to act on different metabolites we again cannot
use its yeast ortholog as a model to understand effects of
variation in human proteins. Pathway information for the
human proteins was previously retrieved and summarized
in Table 2. Pathway information for the yeast proteins was

UniProtKB

Normal

Variation

Position

Substrate ID

Product decreased

Product ID

A2RTX5

t

a

O43175

r

c

532

L-threonine

CID: 6288

L-threonyl-tRNA

SID: 5901

236

3-phospho-D-glycerate

CID: 439183

3-phosphonooxypyruvate

CID: 105

O75891

p

O75908

h

l

107

10-formyltetrahydrofolate

CID: 122347

Tetrahydrofolate

CID: 91443

q

434

cholesterol

CID: 5997

Cholesterol ester

SID: 5537

O75936
O95336

h

q

347

4-trimethylammoniobutanoate

CID: 134

Carnitine

CID: 85

r

c

185

6-phospho-D-glucono-1,5-lactone

CID: 439452

6-phospho-D-gluconate

CID: 91493

O95363

q

x

160

L-phenylalanine

CID: 6140

L-phenylalanyl-tRNA(Phe)

SID: 6321

O95479

r

c

728

Beta-D-glucose 6-phosphate

CID: 439427

6-phospho-D-gluconate

CID: 91493

O95861

a

v

221

PAPS

CID: 10214

Adenylyl sulfate

CID: 10238

P04180

s

n

205

Phosphatidyl choline

SID: 3457

2-lysolecithin

SID: 6900

P09417

y

c

150

Tetrahydrobiopterin

CID: 44257

Dihydrobiopterin

CID: 133246

P13716

r

p

221

5-aminolevulinate

CID: 137

Porphobilinogen

CID: 1021

P22830

d

g

383

Ferrous ion | protoporphyrin IX

CID: 27284 | CID: 4971

Heme

CID: 444097

P23109

h

q

305

Adenylic acid

CID: 6083

Ammonia | inosinic acid

CID: 222 | CID: 8582

P23946

h

r

66

Angiotensin I

CID: 3081372

Angiotensin

CID: 172198

P25092

t

a

618

Guanosine 5'-triphosphate

CID: 6830

Cyclic gmp

CID: 24316

P42357

g

s

165

L-histidine

CID: 6274

Urocanic acid

CID: 736715

P43251

a

s

271

Biocytin

CID: 440721

Biotin | L-lysine

CID: 171548 |CID: 5962

P48637

r

c

125

Glycine | gamma-glutamylcysteine

CID: 750 | CID: 123938

Glutathione

CID: 124886

P49247

d

y

160

D-ribulose 5-phosphate

CID: 439184

Ribose 5-phosphate

CID: 439167

Q02127

t

i

284

L-dihydroorotic acid

CID: 439216

Orotic acid

CID: 967

Q02809

r

h

718

Protein lysine

SID: 5259

Procollagen 5-hydroxy-L-lysine

SID: 4433

Q16873

r

k

104

Leukotriene A4

CID: 5280383

Leukotriene C4

CID: 5280493

Q3SY69

y

x

127

10-formyltetrahydrofolate

CID: 122347

Tetrahydrofolate

CID: 91443

Q6PI48

r

x

266

L-aspartic acid

CID: 5960

L-aspartyl-tRNA(Asp)

SID: 5893

Q8IVS2

s

t

153

Malonyl-CoA

CID: 10663

Malonyl-[acyl-carrier-protein]

SID: 4431

Q8N5D6

y

x

121

Globoside

SID: 124490726

IV3GalNAca-Gb4Cer

SID: 124490727

Q8TDQ7

p

s

182

D-glucosamine phosphate

CID: 440997

Beta-D-fructose 6-phosphate

CID: 440641

Q96C23

r

x

82

Alpha-D-glucose

CID: 79025

Beta-D-glucose

CID: 64689

Q96GX9

g

r

47

S-methyl-5-thio-D-ribulose 1-phosphate

CID: 174549

5-(methylthio)-2,3-dioxopenyl phosphate

CID: 561

Q99487

h

r

314

Platelet-activating factor

SID: 7195

1-alkyl-sn-glycero-3-phosphocholine

SID: 6975
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Table 2 34 proteins with active site nsSNV with substrate/product/pathway relationships ideal for use in metabolomics

Q9NVF9

n

s

94

Ethanolamine

CID: 700

Phosphoethanolamine

CID: 1015

Q9P2T1

g

d

242

Guanylic acid

CID: 6804

Inosinic acid

CID: 8582

Q9Y2Z4

g

s

243

L-tyrosine

CID: 6057

L-tyrosyl-tRNA(Tyr)

SID: 5781

This table provides the UniProtKB accession ID, normal and variable residues, position of the variation and substrate/product pairs with PubChem IDs for 34 proteins with annotated nsSNVs at the active site. These
proteins were chosen for this study based on a one-protein, one-variation, one-substrate/product pair relationship to simplify preliminary modeling by ensuring no complex interactions for the given protein pathway.
NOTE: This table has been updated since the prior publication to include 2 additional proteins which were later identified to meet the criteria.
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Table 2 34 proteins with active site nsSNV with substrate/product/pathway relationships ideal for use in metabolomics (Continued)
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Figure 1 Manual verification of residue conservation at the active site in both human and yeast orthologs. This is the reciprocal best
BLAST hits alignment using yeast protein P05373, Delta-aminolevulinic acid dehydratase for S. cerevisiae, as the query searching against the entire
human proteome. The only human hit is P13716, also delta-aminolevulinic acid for H. sapiens. From genbank annotations, we know the active site
should occur at position 221 in the human sequence, corresponding to position 232 in the yeast sequence. Here we see conservation not only
among the active site residues, but also in the surrounding region, which can also be important in facilitating active site binding.

similarly retrieved from KEGG and recorded. Pathway
conservation is indicated by similar pathway map with
identical substrates and products. All 6 ortholog pairs
were found to participate in the same pathways, acting
on the same substrates and yielding the same products.
Pathway information for these 6 proteins is included in
Table 4. Further support for functional similarity can
be seen in Figure 2, showing evidenced interactions
(collected and curated following guidance by Lim et. al.
[37] with other proteins and the distribution of functional human-yeast orthologs predicted by Isobase [38]
among these subsets. A summary schema of the overall
method used in identification of these 6 candidate proteins is presented in Figure 3.
Yeast 7.0 COBRA modeling

Five of the six identified candidate enzymes were input
into the Yeast 7.0 model available at http://pathway.yeastgenome.org/ [17]. Yeast methylthioribulose-1-phosphate
dehydratase (MDE1), P47095, had no corresponding gene
in the model and was therefore excluded from this analysis. When knockouts are generated in these genes, they
all show normal growth rates except ribose-5-phosphate
Table 3 Conserved residues between human and yeast
orthologs at and around the active site
UniProtKB

Yeast AC

Human
active site

Yeast
active site

Conservation
block

P13716

P05373

221 R

232 R

GDR + CYQLPP

P22830

P16622

383 D

361 D

+ADLV

P48637

Q08220

125 R

128 R

RSDY+

P49247

Q12189

160 D

107 D

DGADEVD

Q96GX9

P47095

47 G

39 G

TGTGGGIS + K

Q9Y2Z4

P48527

243 G

261 G

+Q + GG + DQ

isomerase (RPIA),Q12189, which showed no growth.
However, Yeast 7.0 is not equipped to predict growth
for all of these reactions because some important compounds and cofactors are not currently accounted for
in the model. Findings are summarized in Table 5. (Full
output available in Additional file 1: Table A3).
Modified yeast 7.0 modeling with updated biomass function

Under the consideration that a modeling tool with a more
comprehensive biomass function could provide more
information, we repeated modeling of the 5 relevant
enzymes using a biomass function with added requirements for ferroheme b and charged tRNA(Tyr) in the
mitochondrion. This model was able to implicate three
additional proteins with function in essential reactions:
delta-aminolevulinic acid dehydratase (ALADH), P05373;
mitochondrial ferrochelatase, P16622; and mitochondrial
tyrosine-tRNA ligase, P48527. This additional examination, in conjunction with sequence and pathway conservation, supports our argument for inclusion of the
pertinent pathways in yeast cell models. A summary of
the findings can be seen in Table 5. (see Additional file 1:
Table A3 for full output).
The above Yeast 7.0 results, combined with literature
support, sequence and pathway annotations, maintain our
hypothesis that we should be able to use yeast orthologs
with active site conservation to model the effect of a variation at the active site of its human ortholog in order to
obtain a predictive overview of altered enzyme activity
resulting from the variation. Furthermore, we see the
potential for the utility of this method to improve as
advanced modeling efforts continue to progress.
Biomedical relevance

We hypothesize that nonsynonymous variation in an
enzyme’s active site should have deleterious effects on
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Table 4 Pathway comparison between human candidate proteins and yeast orthologs using KEGG pathway
annotations
Human UniProt Ac

Gene name

Pathways

Yeast
UniProt Ac

Yeast gene
name

Pathway
match?

Details

P13716

ALAD

Porphyrin and clorophyll
metabolism

P05373

HEM2

Yes

Same

No

Pathway only annotated in
yeast; same substrate/product

Yes

Same

No

Pathway only annotated in
yeast; same substrate/product
Same

Biosynthesis of secondary
metabolites
P22830

FECH

Porphyrin and clorophyll
metabolism

P16622

HEM15

Biosynthesis of secondary
metabolites
P48637

GSS

Glutathione metabolism

Q08220

GSH2

Yes

P49247

RPIA

Pentose phosphate pathway

Q12189

RKI1

Yes

Same

No

Pathway only annotated in
yeast; same substrate/product

Biosynthesis of secondary
metabolites
Q96GX9

APIP

Cysteine and methionine
metabolism

P47095

MDE1

Yes

Same

Q9Y2Z4

YARS2

Aminoacyl-tRNA biosynthesis

P48527

MSY1

Yes

Same

This table summarizes the pathway involvement of the six identified candidate proteins. For all 6 proteins, the primary pathway involvement is the same, down to
the same products and substrates and the same place within a pathway. For three of the yeast proteins, however, the pathway annotation in KEGG listed an
additional pathway not annotated for humans: “Biosynthesis of secondary metabolites.” This is likely due to differential annotation between yeast and humans
within KEGG. Because the substrates and products annotated for these pathways were identical to those of the primary pathways, these three proteins were not
excluded and went onto analysis in the yeast FBA modeling.

the enzyme’s activity and function. Although only one of
the six human enzyme SNPs has a direct link to the Online Mendelian Inheritance in Man® database (OMIM®)
[41] in dbSNP (rs28936396 in P48637, human glutathione
synthetase linked to OMIM 266130 – Glutathione synthetase deficiency), all six have literature related to
dysfunction and disease caused by variants found at
other positions within the protein sequence. If our assumptions regarding active site variation are correct,
then nsSNVs at the active site of enzymes involved in
metabolic syndromes will likely alter protein function
and contribute to similar syndromes. Furthermore,
yeast orthologs for these enzymes with strong pathway
and active site conservation may be used to verify the
metabolic effects of such variation with respect to metabolite concentrations. Although the current Yeast 7.0
model supports this hypothesis for RPIA alone, we
argue for inclusion of the pathways and metabolites associated with these proteins in future yeast models based on
consideration of the augmented model findings, literature
and conservation among orthologs. Thus, we present five
potential disease-related proteins with active site nsSNVs
(along with yeast orthologs) in need of laboratory experimentation to validate the veracity of disease related to the
SNV.

oxidation in normal tissue. [42] Synthesis of ribose
5-phosphate from ribulose 5-phosphate via RPI is required for nucleotide and nucleic acid synthesis, and
participates in the downstream production of glycolytic
intermediates [43]. With reduced RPI activity, ribose
5-phosphate becomes unavailable and the necessary
glycolytic metabolites are not produced. Enzyme deficiency results in clinical symptoms of leukoencephalopathy and peripheral polyneuropathy. The RPIA gene has
also been identified to be hypermethylated at CpG sites in
breast cancer [44].
As of 2004, RPI was only the second known inborn
error in the reversible portion of the PPP [45]; the PPP
connects pentose phosphates to glycolytic intermediates.
Furthermore, there are currently only 2 mutations listed
in the Human Gene Mutation Database [46] (accessed
8/22/13) for the RPIA gene, neither of which is the
aspartic acid to tyrosine variation at active site position
160 reported here (rs11549730). RPI has been observed
to be variably conserved among species ranging from
52% similarity between human and E. coli to strong conservation noted between human and other mammals [47]
and RKI1 disruption has been shown to be deleterious to
yeast growth [48].
Human P13716/Yeast P05373

Human P49247/Yeast Q12189

Ribose-5 phosphate isomerase (RPI) participates in the
pentose phosphate pathway (PPP), an alternative pathway
for glucose oxidation accounting for up to 20% of glucose

Delta-aminolevulinic acid dehydratase (ALADH), encoded
by the ALAD gene in humans, catalyzes the first common
step in heme and other tetrapyrrole biosynthesis [49] and
has also been observed to interact with the proteasome
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Figure 2 Similar protein interactions between human and yeast counterparts. Known and predicted protein interactions were retrieved
from IntAct [39] and BioGrid [40] using both human and yeast gene names as query terms. Interactions were organized and edited following
suggestions by Lim et al. [37]. It is interesting to note that although a sizeable portion of predicted interactors are also predicted to have
functional orthology between species, very few of the inter-protein interactions among predicted orthologs were reported for both species.

[50]. The wild-type enzyme exists as a high-activity homooctamer, but alternative lower-activity hexamer assemblies
have been found [51]. In fact, naturally occurring ALAD
porphyria-associated human variants have been shown to
have an increased susceptibility to hexamer-stabilizing inhibitors. Lead-poisoning is also hallmarked by reduced
ALAD activity. 5-aminolevulinate accumulates as a result
of the lowered activity and is responsible for the toxic

effects observed in both disease states. It has been suggested that small molecule stabilization of alternate oligomers (morpheeins) can be used as a therapy to target
delta-aminolevulinic acid dehydratase [52], in addition to
human immunodeficiency virus integrase, tumor necrosis
factor α, mammalian ribonucleotide reductase and other
disease-related proteins for which there is evidence of
alternate, functionally differential oligomers [53].
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Figure 3 Schema of identification of candidate proteins for yeast modeling. The overall method used in this paper was manually
performed, but consists of simple steps and queries which could easily be automated for the performance of future similar studies.

Table 5 Summary of FBA results
Human

Yeast

Reaction tested

Yeast 7.0 results
Knock-out growth

Explanation
Ferroheme b + Yeast 7.0 biomass equation

P13716

P05373

Porphobilinogen synthesis

No FBA growth

P22830

P16622

Protoheme ferrochelatase

No FBA growth

Ferroheme b + Yeast 7.0 biomass equation
−1

P48637

Q08220

Glutathione synthesis

WT growth (μ = 0.1405 hr )

0 flux through reaction in WT (r_0485)

P49247

Q12189

Ribose-5-phosphate isomerization

No FBA growth

Phosphoribosyl-pyrophosphate block

Q96GX9

P47095

Methylthioribulose 1-phosphate dehydratase

Not determined

Gene not present in Yeast 7.0 model

Q9Y2Z4

P48527

Mitochondrial tyrosine-tRNA-ligase reaction

No FBA growth

Mitochondrial tRNA requirement + Yeast
7.0 biomass equation

P47095 impact could not be modeled as the Yeast 7.0 model contains no corresponding gene.
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Mutants in the corresponding yeast HEM2 gene have
been found to disrupt heme biosynthesis, requiring
provision of heme for growth in culture [54]. Yeast and
human ALADH differ with respect to Zn cofactor binding,
thus care is required to ensure homology models account
for this difference in stoichiometry [55]. However, comparison of primary sequences across a diverse array of species
shows a strong degree of similarity in the region of the
active site and a zinc-binding motif [56].
There are many studies discussing ALAD-porphyria
associated mutations [57,58] but responsibility for the
disease state has not yet been assigned to the deletion
at nucleotide position 843. Interestingly, this deletion
in the active site codon also results in a frameshift, further complicating comprehension of potential disease
mechanism(s).
Human P22830/Yeast P16622

Encoded by the FECH gene, ferrochelatase is the final
enzyme in heme biosynthesis, catalyzing the formation
of protoheme IX from protoporphyrin IX and ferrous
iron [59]. Ferrocheletase is important to human health
due to the critical and diverse functions of its product
cofactor, heme. Defects in this enzyme have been related
to erythropoietic protoporphyria (EPP). EPP is a relatively
benign disease with predominant manifestation of photosensitivity, although it has been reported with liver
complications in 2-5% of patients [60]. Biological findings include elevated concentrations of protoporphyrin
in erythrocytes, plasma and feces, and a large amount
of protoporphyrin in the skin [61].
Comparisons between ferrochelatases of multiple species reveal the proteins belonging to human, mouse,
chicken, frog and Drosophila melanogaster to be metalloenzymes with a [2Fe-2S] cofactor, thought to play a
structural stabilizing role in humans [62]. The corresponding bacteria, yeast and plant proteins contain no
iron-sulfur center, but the ferrochelatase from S. cerevisiae
is similar in other respects to eukaryotic ferrochelatases.
Yeast mutants with total or partial FECH activity deficiency and resultant protoporphyrin accumulation have
been isolated [63].
Human Q9Y2Z4/Yeast P48527

Aminoacyl-tRNA synthetases (ARSs) catalyze the linkage
of specific amino acids to their cognate tRNAs [64].
Mitochondrial tyrosyl-tRNA synthetase (TyrRS) is responsible for charging tyrosine to its tRNA. Although
belonging to class I synthetases, tRNA recognition
occurs in a way more common to class II ARSs [65].
Defects in TyrRS are associated with myopathy with
lactic acidosis and sideroblastic anemia 2 (MLASA2).
It has been proposed that diminished aminoacylation
activity of the enzyme leads to decreased mitochondrial
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protein synthesis and mitochondrial respiratory chain
dysfunction [66]. TyrRS also has known involvement
with cell-signaling [67] and angiogenesis [68]. Although
there are multiple known disease-related TyrRS mutants,
it is unclear for some mutants whether pathogenicity
results from dysfunction in aminoacylation or cytokine
activation.
Alignments with TyrRSs from several species reveals
34% identity with yeast and similarly low identity across
the board, with greatest conservation confined to the
N-terminus [69]. Gly-244 and Asp-246 are conserved
among class I synthetase catalytically important residues,
but a total of 8 residues are known to participate in hydrogen bonding [70].
Human Q96GX9/Yeast P47095

Methylthioribulose-1-phosphate dehydratase, encoded by
the APIP (APAF1-interacting protein) gene, catalyzes the
dehydratase step of the methionine salvage pathway,
converting methylthioribulose-1-phosphate into 2,3 dioxomethylthiopentane-1-phosphate [71]. The methionine
salvage pathway recycles sulfur metabolites by recovery
of methionine from methylthioadenosine (MTA). This
pathway plays a critical role in many biological functions
including apoptosis, inflammation and cancer [72].
APIP is highly expressed in skeletal muscle and known
for an anti-apoptotic role [73]. One common APIP SNP
was observed to reduce enzyme activity, resulting in an
increase in cell death in response to Salmonella [74].
Currently excluded from the Yeast 7.0 model, the
MDH1 enzyme is of critical importance to the pathway.
Loss of function leaves the cell with no isozymes for
methionine salvage, as demonstrated in the YeastCyc
pathway/genome database (PGDB) within BioCyc [75].
The enzyme and the entire methionine salvage pathway
seem to be functionally conserved in yeast [76] and should
therefore serve as an adequate model in yeast experimentation to validate predicted loss of function due to the
contained nsSNV.

Conclusions
The method proposed by this series of studies can be
generalized to identify all proteins affected by variation
at functionally important residues, to determine the
availability of orthologous yeast proteins to model the
effects of such variation and, in the future, to predict
and quantify cellular and potentially organismal responses
to the variation. The specific analyses presented here for
demonstration of the method further demonstrate that
nonsynonymous single nucleotide variation at the active
site should disrupt enzyme function and potentially induce disease in yeast. However, to fully and confidently
extrapolate this finding to humans, disruption of enzyme
function must be checked against the effects of zygosity.
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This is currently a limitation imposed by existing data due
to the lack of relevant frequency information for the majority of the variations studied. We have provided 6 sets of
human/yeast enzyme ortholog pairs for which the human
protein has been experimentally shown with nsSNV at the
active site and the yeast enzyme has been verified to share
important conserved properties. Each of these enzymes is
known to have deleterious effects on human physiology
when dysfunctional, but the loss of function has been
directly related in OMIM to only one of the active site
variants, glutathione synthetase. Thus, we present five
viable candidates for variant-related disease discovery.
Preliminary FBA modeling shows predictive support for
one of these enzymes, ribose-5-phosphate isomerase.
Experimental validation of these and similar findings
will continue to increase the knowledge universe, in
turn facilitating the development of more powerful, robust
models. Advances in the technology employed by this
method may enable the long-term creation of metabolite
profiles associated with active site variation for corresponding human and yeast orthologs. Simple biochemical
assays comparing human and yeast metabolite concentrations to the profiles could facilitate detection of active site
non-synonymous variation. This may further lay the
foundation for future diagnostic pipelines to predict
unknown outcomes of active site nsSNVs in these and
other enzymes.

Methods
Datasets and annotated information

Proteomes and all protein subsets were retrieved from
UniProtKB/Swiss-Prot (UniProt release 2012_06 [28]. nsSNV
data were extracted from UniProtKB/Swiss-Prot, dbSNP
(build 135) [29], COSMIC (version 59) [77] and NCI 60 [78]
(accessed June 28, 2012). The SNVDis tool (https://hive.biochemistry.gwu.edu/snpdis.cgi?cmd=dmSnpdis) [12] was used
to retrieve the set of all proteins with nsSNVs at the active
site (as annotated by UniProtKB/Swiss-Prot or CDD). Pathway information was retrieved from Kyoto Encyclopedia
of Genes and Genomes (KEGG) [79] using the Protein
Analysis Through Evolutionary Relationships (PANTHER)
Classification System [80]. Substrate, product and disease
information was gathered manually from KEGG and
UniProtKB/Swiss-Prot. Official names and PubChem
[81] Compound IDs (CIDs) for compounds with
specific chemical structures, or Substance IDs (SIDs) for
those without, were recorded for all substrates and
products.
Analysis
Reciprocal best BLAST hits method

Stand-alone BLAST (version 2.2.27+) [82]was downloaded
from the NCBI website. The yeast (S. cerevisiae) proteome
was downloaded from Uniprot by using the term “Baker's
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yeast [559292]” for the field of Organism[OS], combined
with the term “Complete proteome”’ in the Keyword field.
The set of 559 previously selected human proteins was
retrieved from Uniprot/Swis-protKB in batch mode using
the corresponding accession numbers.
The yeast proteome file was indexed as the database,
and the human protein dataset was used as the query for
the nucleotide-to-nucleotide Blastn algorithm with all
default parameters and E-value higher than 10−5. The
customized script was developed to extract best hits
from the Blastn result. All the yeast proteins that met the
criteria were batch-retrieved from UniprotKB/Swiss-prot
by accession numbers and prepared for the opposite
direction BLAST. Reciprocal best BLAST hits method
was then accomplished by using the selected yeast proteins as the query set to align against the indexed human
proteome database downloaded from Uniprot following
the similar method described above. A human-yeast
ortholog table was generated via a customized script parsing the two-way BLAST results. Thus, only those proteins
which are mutual best hits with p-value higher than 10−5
were marked as the ortholog.
Manual identification of orthologous pairs

Manual examination of BLAST alignment results was
performed to verify residue conservation at and around
the active site, as well as exclusion of proteins with additional homologs. Residue conservation was observed for
all 6 candidate enzymes and reported as the longest continuous sequence conservation block containing the active
site residue. Confirmation of active site annotation across
species was achieved by consulting relevant databases.
Manual confirmation of single-best-match orthologs was
done by visual verification of BLAST results of corresponding human and yeast proteins performed separately
with human and yeast as query species.
FBA procedures

COBRA simulations of the Yeast 7.0 genome-scale model
were performed using Yeast 7.0.0 in the COBRA Toolbox
5.0.0 within MATLAB R2010a. In order to simulate the
effects of knocking out genes YGL040C, YOR176W, and
YPL097W, we added small (0.0005 mmol/gCDW/hr) requirements for ferroheme b and charged tRNA(Tyr) in
the mitochondrion to the Yeast 7.0 biomass function,
creating an augmented biomass function. Experimental
evidence for these deletions drawn from the Saccharomyces Genome Database [83] suggests that YGL040C and
YOR176W null mutants are inviable in large scale surveys,
and that YPL097W mutants are deficient in respiration.
Reference growth rates for wild-type cells lacking gene
knockouts were obtained based on aerobic growth in
glucose minimal media, using both the augmented and
the original Yeast 7.0 biomass function. Additional file 1:
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Table A3 contains fluxes obtained for simulations of wildtype cells using the augmented biomass function and are
labeled as ‘augmented_flux’, while fluxes obtained for simulations of wild-type cells using the Yeast 7.0 biomass
function are labeled as ‘7.00_flux’. Gene knockouts were
simulated by limiting flux through the reaction carried out
by the gene product in question to zero, equaling a total
loss of function for that reaction. All COBRA simulations
employed taxicab norm minimization of fluxes as described in the documentation for the optimizeCbModel
function.

Reviewers' comments
We appreciate the reviewer’s comments from Dr. Daniel
Haft and from Dr. Igor B. Rogozin. We have revised the
manuscript according to your comments and suggestions.
Reviewer 1: Dr. Daniel Haft

Previous work by this group identified 559 human enzymes in which missense mutations replace an enzyme’s
active site residue in rare alleles. Of these, 34 are assigned
a single enzymatic activity rather than a panel of alternate
substrates, with the reaction belonging to a single pathway
in human as documented by KEGG. For this paper, the
collection is winnowed further, to count only those for
which bi-directional best BLAST matches between human
and yeast identify putative ortholog pairs, uncomplicated
by paralogs that could overlap in function. This stringent
filter gets the list down to six enzymes, the topic of this
paper. A tool for flux balance analysis (FBA) is available
for yeast, but not for human. Thus, for these six enzymes,
computation based on a yeast metabolic model leads to
predictions that loss of the same function in human
causes disease.
In one sense, there is no surprise here. Mutations away
from the active site already were known to cause human
disease for five of the six enzymes. Loss of the active site
residue should be no less catastrophic to function than
truncation or frameshift errors. It is possible that a heterozygous active site mutant could produce a currently
unrecognized form of a disease now known only for homozygotes of an incompletely inactivated enzyme, but
that is not the point of the paper. The yeast model is
haploid. Presumably, the implications are for homozygotes
of the mutant form in human.
Authors’ response: Perhaps it wasn’t clear from our
original discussion, but we agree that the haploid yeast
model is only suited to truly “model” homozygous cases.
However, we can envision potential scenarios in which a
haploid model could still provide predictive quantitative
value in assays in highly conserved pathways for loss of
function due to heterozygous mutation at active sites in
humans. We did revisit the text relevant to this issue and
modified it to improve clarity.
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Furthermore, we are not claiming that homozygous
alleles are altogether too rare, in fact the journal article
we cite here (Ng PC1, Levy S, Huang J, Stockwell TB,
Walenz BP, Li K, Axelrod N, Busam DA, Strausberg RL,
Venter JC. Genetic variation in an individual human exome. PLoS Genet. 2008 Aug 15;4(8):e1000160) reports
that just under 50% of all nonsynonymous SNPs in
HuRef are homozygous. However, they go on report that
only about 15% are likely to affect protein function in a
deleterious way and in this case, heterozygous nsSNPS
are two times more likely than homozygotes to be predicted to affect protein activity. Similarly, rare nsSNPS
are twice as likely as common nsSNPs to affect protein
function. Thus, at the active site and other functionally
important residues, protein-affecting SNPs should be
selected against and should be less likely to be observed
in homozygote form.
At your suggestion, we conducted a new PubMed
search and were able to find an article identifying a
homozygous mutation in the catalytic domain of the
MMP2 gene in two sisters with Winchester syndrome
(Rouzier C1, Vanatka R, Bannwarth S, Philip N, Coussement
A, Paquis-Flucklinger V, Lambert JC. A novel homozygous
MMP2 mutation in a family with Winchester syndrome.
Clin Genet. 2006 Mar;69(3):271–6.) The long-term combination of (1) improved classification and annotation of
variation data and (2) simple increase in available studies
should allow us to find these cases and truly study the
quantitative differences of heterozygous and homozygous
states, ultimately helping to develop and refine possible detection assays.
The surprising finding, actually, seems to be that even
under the stringent filtering used – conserved orthologs
from yeast to human of enzymes in a conserved pathway – five of the six genes nominated for study are
associated with described human genetic diseases, not
simply non-viability. The alleles responsible for the
genetic disorders seen in patients may encode enzymes
that retain some residual function, probably more than
an active site mutant retains, allowing for viability.
Rather than presenting a new method to find previously
unrecognized human genetic disease, this paper forms
a field test of the bioinformatics infrastructure one
would need for such a pipeline in the future. If FBA is
not yet available for human cells, the yeast model can
stand in for a few validated human/yeast orthologs.
When it turns out that zeroing activity of several genes
causes no change, it suggests the FBA model needs repair. The authors describe making such repairs, on
their way to completing their proof-of-principle for
notion that a yeast metabolic model, and an infrastructure for data integration, could point the way to the
prediction of diseases that could be caused by certain
missense mutations.
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Authors’ response: Thank you very much for your
detailed comments and review which helped us to focus
our editing efforts and improve our arguments.
Reviewer 2: Dr. Igor B. Rogozin

The authors analyzed nonsynonymous single nucleotide
variations (nsSNVs) in active site residues in human-yeast
protein alignments. This is a promising approach. I do not
see major methodological problems. The only problem
that I see is a discussion about "loss of function via
haploinsufficiency or dominant negative phenotypes". I
understand that this is a complex problem. For example,
the vast majority of disease-associated mutations in the
RPE65 gene (Poliakov E, Gubin AN, Stearn O, Li Y,
Campos MM, Gentleman S, Rogozin IB, Redmond TM.
Origin and evolution of retinoid isomerization machinery
in vertebrate visual cycle: hint from jawless vertebrates.
PLoS One. 2012;7: e49975) are recessive mutations. However a dominant mutation was recently found in this gene.
This and many other examples (including those described
in the paper) suggest that the problem of dominant mutations is extremely complex. I am not sure that the fraction
of such mutations is high although I am not aware of such
estimate in active site residues.
Authors’ response: Thank you for your positive comments
regarding our approach and your general suggestions as
well. We do realize the complexity of this issue and the
necessity of exercising caution when applying models across
organisms without knowing the full characterization of the
deleterious outcome. As I mentioned in my response to Dr.
Haft above, we have discussed the issue of zygosity, phenotype and loss-of-function both prior to the initial submission
and since receipt of your responses. We do not want to ignore the modeling ramifications of differential ploidy, but
we also don’t want to exclude candidate proteins from
downstream quantification steps as it may be possible that
future in vivo assays (developed as a product of the broader
study) can still have some impact on heterozygous disease
states even if in silico models cannot properly simulate
them. We have carefully reread and edited these sections in
response to your comments and we feel that we have clarified our reasons for our treatments of these issues.
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orthology. Table A3. Yeast 7.0 Outputs. Raw outputs from original and
augmented Yeast 7.0 models.
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